ArticleJournal for immunotherapy of cancer2023

PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis.

Zhe Wang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.